• JAK2 regulates paclitaxel resistance in triple negative breast cancers

    20 days ago - By Springer

    Abstract
    We investigated the molecular mechanisms of paclitaxel resistance in TNBC using seven patient-derived xenograft models and TNBC cell lines. Among the seven PDX models, four models showed resistance to paclitaxel. Dysregulation of JAK/STAT pathways and JAK2 copy number gains were observed in the four paclitaxel-resistant PDX tumors. In TNBC cell lines, silencing the JAK2 gene showed a significant but mild synergistic effect when combined with paclitaxel in vitro. However, JAK1/2 inhibitor treatment resulted in restoration of paclitaxel sensitivity in two out of four...
    Read more ...